Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-a-dependent manner. We investigated whether a PPARa agonist, fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate. Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin's glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.

Original languageEnglish
Article numbere30
JournalExperimental and Molecular Medicine
Volume45
Issue number7
DOIs
StatePublished - 16 Aug 2013

Fingerprint

Fenofibrate
Metformin
Rats
Homeostasis
Glucose
Glucose Tolerance Test
Blood Glucose
Lipids
Peroxisome Proliferator-Activated Receptors
Glucagon-Like Peptide 1
Insulin-Secreting Cells
Islets of Langerhans
Metabolism
Eating
Body Weight
Insulin
Injections

Keywords

  • Fenofibrate
  • Glucagon-like peptide-1
  • Goto-kakizaki rats
  • Metformin
  • Peroxisome proliferator-activated receptor alpha

Cite this

@article{bf2f4dc69c204e198b50e631563620aa,
title = "Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats",
abstract = "Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-a-dependent manner. We investigated whether a PPARa agonist, fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate. Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin's glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.",
keywords = "Fenofibrate, Glucagon-like peptide-1, Goto-kakizaki rats, Metformin, Peroxisome proliferator-activated receptor alpha",
author = "Oh, {Tae Jung} and Shin, {Ji Yon} and Gyeonghoon Kang and Park, {Kyong Soo} and Cho, {Young Min}",
year = "2013",
month = "8",
day = "16",
doi = "10.1038/emm.2013.58",
language = "English",
volume = "45",
journal = "Experimental & molecular medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "7",

}

TY - JOUR

T1 - Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats

AU - Oh, Tae Jung

AU - Shin, Ji Yon

AU - Kang, Gyeonghoon

AU - Park, Kyong Soo

AU - Cho, Young Min

PY - 2013/8/16

Y1 - 2013/8/16

N2 - Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-a-dependent manner. We investigated whether a PPARa agonist, fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate. Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin's glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.

AB - Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-a-dependent manner. We investigated whether a PPARa agonist, fenofibrate, exhibits an additive or synergistic effect on glucose metabolism, independent of its lipid-lowering effect, when added to metformin. Non-obese diabetic Goto-Kakizaki (GK) rats were divided into four groups and treated for 28 days with metformin, fenofibrate, metformin plus fenofibrate or vehicle. The random blood glucose levels, body weights, food intake and serum lipid profiles were not significantly different among the groups. After 4 weeks, metformin, but not fenofibrate, markedly reduced the blood glucose levels during oral glucose tolerance tests, and this effect was attenuated by adding fenofibrate. Metformin increased the expression of the GLP-1 receptor in pancreatic islets, whereas fenofibrate did not. During the intraperitoneal glucose tolerance tests with the injection of a GLP-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. In conclusion, fenofibrate did not confer any beneficial effect on glucose homeostasis but reduced metformin's glucose-lowering activity in GK rats, thus discouraging the addition of fenofibrate to metformin to improve glycemic control.

KW - Fenofibrate

KW - Glucagon-like peptide-1

KW - Goto-kakizaki rats

KW - Metformin

KW - Peroxisome proliferator-activated receptor alpha

UR - http://www.scopus.com/inward/record.url?scp=84883021915&partnerID=8YFLogxK

U2 - 10.1038/emm.2013.58

DO - 10.1038/emm.2013.58

M3 - Article

C2 - 23827952

AN - SCOPUS:84883021915

VL - 45

JO - Experimental & molecular medicine

JF - Experimental & molecular medicine

SN - 1226-3613

IS - 7

M1 - e30

ER -